PIC Therapeutics

PIC Therapeutics is a biotechnology company dedicated to fundamentally transforming cancer treatment by developing a new generation of therapies based on the regulation of RNA translation. Their precision technology-based therapies target the "master switch" of cancer signaling pathways, selectively blocking the production of oncogenic proteins by modulating the pre-initiation complex (PIC) that drives their mRNA translation. PIC Therapeutics' selective approach has the potential to simultaneously regulate multiple oncogenic drivers, paving the way for the development of powerful next-generation cancer treatments.